Healthcare business law · Updated

Telehealth prescribing rules: who may prescribe what, how and from where for patients in North Carolina

A clinician may prescribe by telehealth to a patient in North Carolina if licensed in North Carolina (the Medical Board treats care as delivered where the patient is located), after an appropriate evaluation that meets the same standard of care as an office visit. The evaluation does not have to be in person, but prescribing "based solely on static online questionnaires" is not acceptable (NCMB 5.1.4). Physician assistants and nurse practitioners prescribe within their supervision or collaborative practice arrangements. Controlled substances add federal rules: a DEA registration, generally in the state where the patient is located, and, under the Ryan Haight Act, an in-person evaluation or a recognized telemedicine route. A temporary DEA rule that allows Schedule II-V prescribing by telemedicine without an in-person visit runs until December 31, 2026. A North Carolina pharmacist may fill only a prescription issued "in the context of a patient-prescriber relationship" (21 NCAC 46 .1801).

Prescribing by telehealth to a patient located in North Carolina (as of November 16, 2026)
QuestionDrugs that are not controlled substancesControlled substances (Schedules II-V)
LicenseA North Carolina license, unless an exception applies (NCMB 5.1.4)The same
First visit by telehealthAllowed if the evaluation meets the standard of care; no prior in-person meeting is requiredFederal law also applies: allowed without an in-person evaluation until December 31, 2026 under 21 CFR 1307.41; after that only by a route in the Ryan Haight Act unless DEA acts (details)
Online questionnaire aloneNot acceptable (NCMB 5.1.4; 4.1.1)Not acceptable
DEA registrationNot required (NCMB FAQ)Required, generally in the state where the patient is located at the time of care
North Carolina controlled-substance registrationNoneNone: North Carolina has no state registration separate from DEA's
North Carolina CSRS checkNot requiredBefore prescribing a Schedule II or III opioid or narcotic, review the patient's 12-month history, as the Medical Board describes the STOP Act
PharmacyFills only a valid order (21 NCAC 46 .1801); an out-of-state pharmacy needs a North Carolina permit to ship in (46 .1607)The same, plus the federal prescription rules in 21 CFR part 1306
Who can prescribe, and on what terms (North Carolina)
PrescriberPrescribing authorityControlled substances
Physician (NC Medical Board license)Within the standard of care and the Board's position statements on telemedicine (5.1.4) and prescribing (4.1.1, 4.1.2)Own DEA registration; a physician who supervises PAs or NPs who prescribe controlled substances needs a registration with "the same schedule(s)" (4.1.2)
Physician assistant"may prescribe, order, procure, dispense, and administer drugs and medical devices" on the conditions in 21 NCAC 32S .0212, including written supervisory arrangementsOwn "valid Drug Enforcement Administration (DEA) registration"; the supervising physician holds "at least the same schedule(s)"; none for the PA, the supervising physician, family or household
Nurse practitionerDrugs and devices listed in the collaborative practice agreement for each practice site; anything else only on a specific order from a supervising physician given beforehand (21 NCAC 32M .0109)As established in the collaborative practice agreement; the NP's DEA number on each controlled prescription; the primary supervising physician's schedules "equal to or greater than" the NP's

Licensure: the patient's location decides

"The Board deems the practice of medicine to occur in the state where the patient is located", so anyone using telemedicine to treat a patient in North Carolina "should be licensed in North Carolina unless an appropriate exception, such as those listed below, applies" (NCMB 5.1.4, amended March 2024). The two listed exceptions are narrow: "provider-to-provider consultations across state lines" where a North Carolina licensee stays responsible for the patient and the out-of-state provider consults "on an irregular basis"; and "episodic follow-up care in which the patient is temporarily located in North Carolina but has an established relationship with an out-of-state provider", such as a student or a vacationer.

The prescriber can be anywhere: "Licensees need not reside in North Carolina if they have a valid, current license with the Board." The reverse also holds. A North Carolina licensee treating a patient in another state "should check with the state licensing board in the state where they intend to provide care", and the Board notes that "Most states require medical providers to be licensed in the state where the patient is located". For multi-state models, see telehealth and MSO structures.

The evaluation before a telehealth prescription

The Medical Board applies the same standard of care to telehealth:"The Board does not endorse a separate standard of care for telemedicine." Licensees treating North Carolina patients by telemedicine "are encouraged to provide, or rely upon, an appropriate evaluation prior to diagnosing and/or treating the patient", and "This evaluation need not be in-person if the licensee employs technology sufficient to accurately diagnose and treat the patient in conformity with the applicable standard of care." A relationship "may be established via either synchronous or asynchronous telemedicine technologies without any requirement of a prior in-person meeting, so long as the standard of care is met" (NCMB 5.1.4).

The limit is the questionnaire. "Diagnosis, prescribing, or other treatment based solely on static online questionnaires, or those that do not obtain all of the information necessary to meet applicable standards of care, are not acceptable." The Board's prescribing statement says the same in older words: prescribing "to individuals the licensee has never met based solely on answers to a set of questions, as is common in Internet or toll-free telephone prescribing, is inappropriate and unprofessional". It allows "An appropriate prescription in a telemedicine encounter where the threshold information to make a reasonably presumptive treatment plan has been obtained", and "Ordinarily" expects "an appropriate history and physical examination", a working diagnosis and a therapeutic plan, documented (NCMB 4.1.1, amended July 2024).

Three more points from the Board apply to every telehealth prescriber. "No prescription should be issued for a patient in the absence of a documented and established licensee-patient relationship", and "The practice of pre-signing prescriptions, either written or electronic, is unacceptable" (NCMB 4.1.2, amended July 2025). Encounters "conducted exclusively through telemedicine may not be deemed suitable in specific circumstances, including but not limited to, the treatment of pain." And the patient needs a way back: "Licensees have the responsibility to refer patients for in-person follow-up care", and "It is insufficient for licensees to simply refer all patients to the emergency department" (5.1.4).

Physician assistants and nurse practitioners

Both prescribe in North Carolina, on different terms (table above). A physician assistant prescribes under written supervisory arrangements and, for controlled substances, needs "a valid Drug Enforcement Administration (DEA) registration" with a supervising physician who holds "at least the same schedule(s) of controlled substances" (21 NCAC 32S .0212). A nurse practitioner prescribes the "Drugs and devices" listed "in the collaborative practice agreement" for each practice site; a drug not on the list needs "a specific written or verbal order obtained from a primary or back-up supervising physician before the prescription or order is issued", recorded in the chart (21 NCAC 32M .0109). For a telehealth platform, in our reading, that makes the collaborative practice agreement part of the formulary: a nurse practitioner prescribing a drug the agreement does not list, without that prior order, is outside the rule however good the visit was.

Controlled substances: the federal layer

For a controlled substance, federal law adds a second test. No controlled substance that is a prescription drug "may be delivered, distributed, or dispensed by means of the Internet without a valid prescription", which means one issued by "a practitioner who has conducted at least 1 in-person medical evaluation of the patient" or by a covering practitioner (21 U.S.C. 829(e)). The rule does not apply to a practitioner "engaged in the practice of telemedicine", a term limited to the situations listed in 21 U.S.C. 802(54).

Until the end of the day on December 31, 2026, a temporary DEA and HHS rule lets "a DEA-registered practitioner" prescribe "schedule II-V controlled substances via telemedicine" without an in-person evaluation, if the prescription is for a legitimate medical purpose, follows a communication through an interactive telecommunications system, and meets DEA's other prescription rules (21 CFR 1307.41; 90 FR 61301). As of November 16, 2026 DEA had not published a fifth extension or a final special registration rule. A separate final rule allows buprenorphine for opioid use disorder by telemedicine, including audio-only, after a check of the patient's state prescription monitoring program (90 FR 6504). What changes after December 31 is covered in DEA telemedicine prescribing after December 31, 2026.

Which drugs this reaches is a schedule question. Testosterone is listed in Schedule III (21 CFR 1308.13) and phentermine in Schedule IV (21 CFR 1308.14); a drug that is not on the federal schedules is outside these DEA rules, though every state rule above still applies.

DEA registration and the patient's state

The Medical Board's FAQ is direct: "Unless an exception exists, the DEA requires all prescribers to hold a state-specific DEA registration in the state where the patient is located at the time of care." A DEA registration "is only required if you will be prescribing controlled substances", and North Carolina has no state registration of its own: "While some states have an additional prescribing registration or permit separate from the DEA registration process, North Carolina does not" (NCMB FAQ). DEA's own guidance says the same and notes that "a number of exceptions to that requirement exist" (DEA, July 28, 2020).

The FAQ also covers sending a controlled-substance prescription to a pharmacy in another state: it is generally allowed if "(1) you have an established relationship with the patient that originated in North Carolina, (2) you hold a NC medical license, and (3) you hold a DEA registration specific to North Carolina", subject to "restrictions, limitations, or special requirements based on the laws where the pharmacy is located."

North Carolina's opioid prescribing checks

The Medical Board expects telehealth prescribers of controlled substances to "comply with all relevant federal and state laws" and "to participate in the Controlled Substances Reporting System" (5.1.4). As the Board describes the STOP Act, before prescribing "a Schedule II or Schedule III opioid or narcotic", "practitioners are required to review a patient's 12-month prescription history in the NC CSRS"; the Board announced that "Mandatory use goes into effect on July 7, 2021" (NCMB). The Board's FAQ on the same Act describes 5-day and 7-day limits on initial prescriptions for acute and post-surgical pain, and mandatory electronic prescribing of Schedule II and III opioids from January 1, 2020; it also notes that "NC CSRS allows prescribers to register delegates" to run queries (NCMB FAQ, revised September 2019). The FAQ adds that stimulants are not "targeted controlled substances" for these provisions.

The pharmacy side

A prescription is only as good as the pharmacy's willingness to fill it. Under the Board of Pharmacy's rule, "A prescription order is valid only if it is a lawful order for a drug, device, or medical equipment issued by a health care provider for a legitimate medical purpose, in the context of a patient-prescriber relationship, and in the course of legitimate professional practice as recognized by the occupational licensing board governing the health care provider." A pharmacist has "a right to refuse to fill or refill a prescription order if doing so would be contrary to his or her professional judgment", and must not fill one where "there is or reasonably may be a question regarding the order's accuracy, validity, authenticity, or safety for the patient" (21 NCAC 46 .1801). The Medical Board reminds prescribers that "the pharmacist has a corresponding responsibility with the prescriber" (4.1.2).

A mail-order or online pharmacy outside North Carolina "may not ship, mail, or deliver in any manner even a single dispensed legend drug" into the state "until it receives a permit from the Board", and a business shipping from several locations "shall register each pharmacy separately" (21 NCAC 46 .1607).

Where telehealth prescribing models go wrong

This is our reading of the patterns that cause trouble under the rules above:

  • An intake form that ends in a prescription with no real evaluation: the Medical Board calls questionnaire-only prescribing "not acceptable".
  • Prescribers licensed in another state treating patients in North Carolina without a North Carolina license or a listed exception.
  • A DEA registration in the prescriber's home state used for patients in other states.
  • Nurse practitioners prescribing drugs that their collaborative practice agreement does not list.
  • A business plan that assumes the temporary DEA rule will still be in force after December 31, 2026.
  • Prescriber pay set per prescription or per approved patient, which raises kickback and fee-splitting questions (see the Anti-Kickback Statute for GLP-1 and peptide clinics).

Common questions

Can a telehealth provider prescribe medication in North Carolina?

Yes, if the provider is licensed in North Carolina (or fits a listed exception) and makes an appropriate evaluation that meets the same standard of care as an office visit. The evaluation can be by video or other telemedicine technology; prescribing based solely on a static online questionnaire is not acceptable to the NC Medical Board.

Can telehealth providers prescribe controlled substances?

Yes, with federal conditions. The prescriber needs a DEA registration, generally in the patient's state. Until December 31, 2026 a temporary DEA rule allows Schedule II-V prescribing by telemedicine without an in-person evaluation; after that, unless DEA acts, the Ryan Haight Act's in-person rule and its narrow exceptions apply again, apart from the buprenorphine and VA rules.

Do I need an in-person visit before a telehealth prescription in North Carolina?

Not for North Carolina purposes: the Medical Board allows a licensee-patient relationship to be established by telemedicine without a prior in-person meeting, so long as the standard of care is met. For controlled substances, federal law may require one after December 31, 2026.

Can a doctor licensed in another state prescribe by telehealth to a patient in North Carolina?

Generally not without a North Carolina license. The Medical Board treats care as delivered where the patient is located. Its listed exceptions cover irregular provider-to-provider consultations and episodic follow-up for a patient temporarily in North Carolina with an established out-of-state provider.

Can a nurse practitioner or physician assistant prescribe by telehealth in North Carolina?

Yes, within their own rules. A nurse practitioner prescribes the drugs and devices listed in the collaborative practice agreement (others only on a prior specific order from a supervising physician); a physician assistant prescribes under written supervisory arrangements. For controlled substances each needs a DEA registration, and the supervising physician must hold at least the same schedules.

Will a pharmacy fill a telehealth prescription?

A North Carolina pharmacist fills only a valid order: one issued for a legitimate medical purpose, in the context of a patient-prescriber relationship, in the course of legitimate professional practice as the prescriber's licensing board recognizes it. A pharmacist may refuse an order that is contrary to professional judgment.

Update log

  • November 16, 2026. Published. The NC Medical Board's position statements 5.1.4, 4.1.1 and 4.1.2, its DEA FAQ, CSRS notice and STOP Act FAQ, the PA, NP and Board of Pharmacy rules (21 NCAC 32S .0212, 32M .0109, 46 .1801 and 46 .1607, Cornell LII copies), 21 U.S.C. 829 and 802 (uscode.house.gov, current through Pub. L. 119-124), the DEA rules and guidance, and 21 CFR 1308.13 and 1308.14, all read at the source November 16, 2026. North Carolina's statutes are described as the Medical Board describes them.

Sources

Related

Published November 16, 2026; updated November 16, 2026. General information, not legal advice. See the disclaimer.

Building or reviewing a telehealth prescribing model?

DPS Law reviews telehealth intake and prescribing workflows, prescriber, collaborative practice and pharmacy agreements, and licensure and DEA registration plans under North Carolina and federal law. Our attorney is licensed in North Carolina only; for patients in another state, talk to a lawyer licensed there.

Telehealth and MSO structures